Key result
Adjuvant multiagent chemotherapy and irradiation after initial surgery for pediatric synovial sarcoma resulted in a 5-year event-free survival of 74.2%.
Why the study?
Does multiagent chemotherapy and irradiation after initial surgery improve event-free survival in pediatric and adolescent patients with synovial sarcoma?
Population
31 pediatric and adolescent patients with synovial sarcoma, median age 14 years, male-female ratio 1:1.6
Design
Cohort
Follow-up
median 101 months (range, 77-131 months)
Authors
Loading...
Supports adjuvant chemotherapy and irradiation in pediatric synovial sarcoma; leaves open randomized confirmation of benefit.
Cohort (n=31)
Yes
Does multiagent chemotherapy and irradiation after initial surgery improve event-free survival in pediatric and adolescent patients with synovial sarcoma?
Adjuvant chemotherapy and irradiation after initial nonmutilating surgery appears to improve long-term event-free survival in pediatric and adolescent patients with synovial sarcoma.
Ladenstein et al. (1993) conducted a cohort in Synovial sarcoma (n=31). Multiagent chemotherapy and irradiation after initial tumor excision or biopsy was evaluated on Overall event-free survival (EFS) at 5 years. Adjuvant multiagent chemotherapy and irradiation after initial surgery for pediatric synovial sarcoma resulted in a 5-year event-free survival of 74.2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: